Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Infusão Intravenosa de Lidocaína em Cirurgia de Fusão Lombar

23 de setembro de 2026 atualizado por: Ankara City Hospital Bilkent

Efeito da Infusão Intravenosa Intraoperatória de Lidocaína no Consumo Pós-operatório de Opioides e na Recuperação Após Cirurgia de Fusão Lombar: Um Ensaio Controlado Randomizado

Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.

This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.

The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.

Visão geral do estudo

Status

Recrutamento

Descrição detalhada

Lumbar fusion surgery is frequently associated with significant postoperative pain and often requires high doses of opioid analgesics during the perioperative period. Opioid administration may lead to several adverse effects including postoperative nausea and vomiting, sedation, respiratory depression, and delayed recovery. Therefore, multimodal analgesia strategies are increasingly used to improve postoperative pain control and reduce opioid requirements.

Intravenous lidocaine infusion has gained attention as an adjunct component of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. Previous clinical studies have suggested that perioperative systemic lidocaine may reduce postoperative pain intensity, decrease opioid consumption, and improve recovery after surgery. However, evidence regarding its effectiveness in patients undergoing lumbar fusion surgery remains limited.

This prospective, randomized, placebo-controlled study will include adult patients aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for elective lumbar fusion surgery. Participants will be randomly allocated into two groups. Patients in the lidocaine group will receive an intravenous lidocaine bolus followed by continuous lidocaine infusion during surgery, whereas patients in the control group will receive an equivalent volume of normal saline infusion. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Postoperative pain will be assessed using the Numerical Rating Scale (NRS). Rescue analgesia will be administered when clinically indicated.

The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores at predefined time points, time to first rescue analgesic requirement, postoperative nausea and vomiting incidence, quality of recovery measured by QoR-15, post-anesthesia care unit length of stay, time to mobilization, and hospital length of stay.

In addition, inflammatory and oxidative stress responses associated with surgery and lidocaine administration will be evaluated. Blood samples will be collected preoperatively and at 6 and 24 hours postoperatively to measure interleukin-6 (IL-6) levels and markers of thiol-disulfide homeostasis.

Tipo de estudo

Intervencional

Inscrição (Estimado)

110

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥18 years
  • Scheduled for elective lumbar fusion surgery under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Ability to provide written informed consent

Exclusion Criteria:

  • Refusal to participate in the study
  • ASA physical status ≥IV
  • Body mass index >35 kg/m²
  • Known allergy or hypersensitivity to lidocaine or study medications
  • Severe cardiac, hepatic, or renal disease
  • Pregnancy
  • Neurological disorders affecting pain assessment
  • Chronic opioid use
  • Use of opioids or antiemetic drugs before surgery
  • Inability to cooperate with postoperative assessments

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Lidocaine Infusion

Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg/kg/h throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia.

Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

Comparador de Placebo: Placebo (Normal Saline)

Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia.

An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Cumulative postoperative opioid consumption within the first 24 hours after surgery
Prazo: 0 to 24 hours after surgery

Cumulative opioid consumption during the first 24 postoperative hours will be evaluated. Rescue analgesia will be administered as intravenous tramadol (100 mg) when the Numerical Rating Scale (NRS) pain score is ≥4. The cumulative tramadol dose administered during this period will be recorded in milligrams (mg).

0 to 24 hours after surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Intraoperative remifentanil consumption
Prazo: From induction of anesthesia to the end of surgery

Cumulative remifentanil consumption during surgery will be recorded in micrograms (µg).

From induction of anesthesia to the end of surgery
Postoperative pain intensity
Prazo: At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery

Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain).

At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
Time to first rescue analgesic requirement
Prazo: Within the first 24 hours after surgery

Time from the end of surgery to the first administration of rescue intravenous tramadol will be recorded.

Within the first 24 hours after surgery
Quality of recovery
Prazo: Preoperative baseline and 24 hours after surgery

Quality of recovery will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire, a validated patient-reported outcome measure assessing postoperative recovery. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery.

Preoperative baseline and 24 hours after surgery
Postoperative nausea and vomiting incidence
Prazo: 0-24 hours after surgery

The incidence of postoperative nausea and/or vomiting and the requirement for rescue antiemetic treatment will be recorded.

0-24 hours after surgery
Post-anesthesia care unit length of stay
Prazo: Immediate postoperative period (up to 24 hours after surgery)

Duration of stay in the post-anesthesia care unit will be recorded in minutes.

Immediate postoperative period (up to 24 hours after surgery)
Time to mobilization
Prazo: Up to 24 hours after surgery

Time from the end of surgery to the first mobilization will be recorded.

Up to 24 hours after surgery
Serum interleukin-6 (IL-6) levels
Prazo: Preoperatively and at 6 and 24 hours after surgery

Serum interleukin-6 (IL-6) levels will be measured to evaluate the inflammatory response.

Preoperatively and at 6 and 24 hours after surgery

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Thiol-disulfide homeostasis parameters
Prazo: Preoperatively and at 6 and 24 hours after surgery

Native thiol, total thiol, and disulfide levels will be measured to evaluate oxidative stress and thiol-disulfide homeostasis.

Preoperatively and at 6 and 24 hours after surgery
Length of hospital stay
Prazo: Through hospital discharge, an average of 5 days

Total duration of hospitalization will be recorded in days.

Through hospital discharge, an average of 5 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Gokhan Erdem, MD, PhD, Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de abril de 2026

Conclusão Primária (Estimado)

1 de janeiro de 2027

Conclusão do estudo (Estimado)

1 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

16 de março de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de março de 2026

Primeira postagem (Real)

23 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

23 de setembro de 2026

Última verificação

1 de março de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

No plan to share individual participant data.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever